注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

liusongjifan2的博客

读书是同智者交流;读书是对神奇世界的探访;读书是和挚友娓娓谈心 !

 
 
 

日志

 
 

【转载】Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening  

2015-12-19 13:41:05|  分类: 医学知识 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |
Search Terms Search within      All Content     Article Title, Abstract, Keywords     Authors     Article Title     Abstract   Advanced Search
【转载】Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening - liusongjifan2 - liusongjifan2的博客
 
Articles

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

Prof Ian J Jacobs, FRCOG*correspondenceemail
,
 Prof Usha Menon, FRCOG*correspondenceemail
,
 Andy Ryan, PhD
,,,,
 Prof Nazar N Amso, PhD
,,,,,,,
 Stephen Dobbs, FRCOG
,,,
 Keith Godfrey, FRCOG
,,,,,
 Howard Jenkins, FRCOG?
,,
 Simon Leeson, FRCOG
,,,
 Alberto Lopes, FRCOG
,
 Tim Mould, FRCOG
,
 John Murdoch, FRCOG
,
 David Oram, FRCOG
,,,
 Ian Scott, FRCOG
,
 Mourad W Seif, FRCOG
,,
Naveena Singh, FRCPath
,,,,,,
 Prof Lesley Fallowfield, DPhil
,
 Prof Alistair J McGuire, PhD
,
 Prof Stuart Campbell, DSc
,
 ProfMahesh Parmar, DPhil?
,
*Contributed equally
?Contributed equally
?Mr Jenkins died in June, 2015
Show all authors
Open AccessArticle has an altmetric score of 334

Open access funded by Medical Research Council

showArticle Info

Publication History
Published Online:17 December 2015
? 2015 Jacobs Menon et al. Open Access article published under the terms of CC BY. Published by Elsevier Ltd.
Jump to SectionIntroductionMethodsResultsDiscussionSupplementary MaterialReferences

Summary

Background

Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5 years. We designed this trial to establish the effect of early detection by screening on ovarian cancer mortality.

Methods

In this randomised controlled trial, we recruited postmenopausal women aged 50–74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland. Exclusion criteria were previous bilateral oophorectomy or ovarian malignancy, increased risk of familial ovarian cancer, and active non-ovarian malignancy. The trial management system confirmed eligibility and randomly allocated participants in blocks of 32 using computer-generated random numbers to annual multimodal screening (MMS) with serum CA125 interpreted with use of the risk of ovarian cancer algorithm, annual transvaginal ultrasound screening (USS), or no screening, in a 1:1:2 ratio. The primary outcome was death due to ovarian cancer by Dec 31, 2014, comparing MMS and USS separately with no screening, ascertained by an outcomes committee masked to randomisation group. All analyses were by modified intention to screen, excluding the small number of women we discovered after randomisation to have a bilateral oophorectomy, have ovarian cancer, or had exited the registry before recruitment. Investigators and participants were aware of screening type. This trial is registered with ClinicalTrials.gov, number NCT00058032.

Findings

Between June 1, 2001, and Oct 21, 2005, we randomly allocated 202?638 women: 50?640 (25·0%) to MMS, 50?639 (25·0%) to USS, and 101?359 (50·0%) to no screening. 202?546 (>99·9%) women were eligible for analysis: 50?624 (>99·9%) women in the MMS group, 50?623 (>99·9%) in the USS group, and 101?299 (>99·9%) in the no screening group. Screening ended on Dec 31, 2011, and included 345?570 MMS and 327?775 USS annual screening episodes. At a median follow-up of 11·1 years (IQR 10·0–12·0), we diagnosed ovarian cancer in 1282 (0·6%) women: 338 (0·7%) in the MMS group, 314 (0·6%) in the USS group, and 630 (0·6%) in the no screening group. Of these women, 148 (0·29%) women in the MMS group, 154 (0·30%) in the USS group, and 347 (0·34%) in the no screening group had died of ovarian cancer. The primary analysis using a Cox proportional hazards model gave a mortality reduction over years 0–14 of 15% (95% CI ?3 to 30; p=0·10) with MMS and 11% (?7 to 27; p=0·21) with USS. The Royston-Parmar flexible parametric model showed that in the MMS group, this mortality effect was made up of 8% (?20 to 31) in years 0–7 and 23% (1–46) in years 7–14, and in the USS group, of 2% (?27 to 26) in years 0–7 and 21% (?2 to 42) in years 7–14. A prespecified analysis of death from ovarian cancer of MMS versus no screening with exclusion of prevalent cases showed significantly different death rates (p=0·021), with an overall average mortality reduction of 20% (?2 to 40) and a reduction of 8% (?27 to 43) in years 0–7 and 28% (?3 to 49) in years 7–14 in favour of MMS.

Interpretation

Although the mortality reduction was not significant in the primary analysis, we noted a significant mortality reduction with MMS when prevalent cases were excluded. We noted encouraging evidence of a mortality reduction in years 7–14, but further follow-up is needed before firm conclusions can be reached on the efficacy and cost-effectiveness of ovarian cancer screening.

Funding

Medical Research Council, Cancer Research UK, Department of Health, The Eve Appeal.

  评论这张
 
阅读(9)| 评论(0)
推荐 转载

历史上的今天

在LOFTER的更多文章

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017